

# Imaging in Obesity/ Weight Loss Trials

Capture Body Composition Imaging  
Biomarkers with Confidence




## Meeting Today's Obesity Trial Needs

The development of GLP-1 agonists and other therapies for weight loss and obesity is evolving and so is the advancement of imaging biomarkers for body composition profiling. The options to delineate and quantify muscle and lean mass are getting more sophisticated, so determining which imaging modality, anatomical coverage, and analysis methods to use can be critical to your obesity clinical trial outcomes.

Perceptive Imaging combines the right experience and the right people to help you navigate the nuances of imaging in weight loss clinical trials and to drive the success of your development program.

### Perceptive Imaging Experience

Perceptive has provided imaging services to quantify lean and/or adipose tissue in nearly **80 clinical trials** to date, contributing to **8 regulatory approvals.**



You can rely on the scientific experts at Perceptive Imaging to reliably measure muscle and fat changes in the whole body or at specific anatomic locations. Perceptive's expertise spans the gamut of imaging that's required to demonstrate safety and efficacy during obesity clinical trials, including:

- ▶ Whole body lean and fat mass (DXA)
- ▶ Subcutaneous and visceral fat (DXA, MRI or CT)
- ▶ Intramuscular fat fraction (MRI)
- ▶ Muscle volume (CT or MRI)
- ▶ Liver, spleen or pancreatic volume
- ▶ Liver, pancreas or spleen fat fraction
- ▶ Cardiac safety (MRI or ECHO)
- ▶ Bone age (X-ray)
- ▶ Bone density (DXA BMD)
- ▶ Functional brain changes (fMRI)

## Meet Perceptive's Obesity Imaging Leadership Team



**Sarah (Sally) Warner, PhD**  
Sr. Director, Scientific and Medical Affairs



**Farhan Syed, PhD**  
Sr. Medical Director

## How can we help?

To learn how our obesity/weight loss imaging experts can help you achieve your clinical development objectives, contact:

▶ [hello@perceptive.com](mailto:hello@perceptive.com)